You need to be logged in to view this video
Biotech M&A results in overnight premiums of 50-200%. Find out how MTSL has discovered these biotech winners for our subscribers.
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
Filter By Category
Filter By Keywords